Progress of the role of Axl in drug resistance of leukemia and the targeted therapy

刘毅,刘代红
DOI: https://doi.org/10.3760/cma.j.cn115356-20200318-00071
2020-01-01
Abstract:Axl, a member of receptor tyrosine kinase TAM (Tyro3, Axl and Mertk) family, has been found to be up-regulated in various types of tumors such as non-small cell lung cancer, gastric cancer, breast cancer and leukemia. Overexpression and activation of Axl can participate in the processes of promoting epithelial-to-mesenchymal transition, tumor angiogenesis, resistance to chemoradiotherapy and targeted drugs, and decreasing anti-tumor immune response, thus it becomes a biomarker for predicting tumor prognosis and target for anti-tumor therapy. This article reviews the structure and activation of Axl, the relationship of Axl with drug resistance and prognosis of leukemia, and the Axl-targeted drugs.
What problem does this paper attempt to address?